CN109475558A - 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 - Google Patents

通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 Download PDF

Info

Publication number
CN109475558A
CN109475558A CN201780046536.9A CN201780046536A CN109475558A CN 109475558 A CN109475558 A CN 109475558A CN 201780046536 A CN201780046536 A CN 201780046536A CN 109475558 A CN109475558 A CN 109475558A
Authority
CN
China
Prior art keywords
drug
cancer
compound
cell
folate receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780046536.9A
Other languages
English (en)
Chinese (zh)
Inventor
P.S.罗
B.王
C.P.利蒙
Y.J.卢
L.W.惠勒二世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Endocyte Inc
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Priority to CN202210697024.1A priority Critical patent/CN114903890A/zh
Publication of CN109475558A publication Critical patent/CN109475558A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
CN201780046536.9A 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 Pending CN109475558A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210697024.1A CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
US62/341587 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210697024.1A Division CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN109475558A true CN109475558A (zh) 2019-03-15

Family

ID=60412652

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780046536.9A Pending CN109475558A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN202210697024.1A Pending CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210697024.1A Pending CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Country Status (8)

Country Link
US (2) US20190216935A1 (cg-RX-API-DMAC7.html)
EP (1) EP3463367A4 (cg-RX-API-DMAC7.html)
JP (1) JP7278777B2 (cg-RX-API-DMAC7.html)
KR (1) KR102489277B1 (cg-RX-API-DMAC7.html)
CN (2) CN109475558A (cg-RX-API-DMAC7.html)
AU (1) AU2017271550B2 (cg-RX-API-DMAC7.html)
IL (1) IL263059B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017205661A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019317278B2 (en) * 2018-08-07 2025-05-22 Purdue Research Foundation Rejuvenation of CAR T cell
CN114269346A (zh) * 2019-07-08 2022-04-01 普渡研究基金会 用于治疗和预防纤维化疾病状态和癌症的化合物和方法
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
EP4271378A4 (en) * 2021-01-04 2026-03-11 Purdue Research Foundation METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT
CN118829726A (zh) 2022-03-08 2024-10-22 科纳斯特股份有限公司 包含胶原酶、钙、组氨酸及甘氨酸的组合物及胶原酶的稳定化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
CA2793657A1 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
WO2012149416A2 (en) * 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
WO2013082591A1 (en) * 2011-12-02 2013-06-06 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
EP3223860A4 (en) * 2014-11-25 2018-08-01 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
(美)莱登著: "《肿瘤转移 生物学基础与治疗》", 31 May 2015, 复旦大学出版社 *
FRANCESCO DE SANCTIS等: "MDSCs in cancer: conceiving new prognostic and therapeutic targets", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *
GERRIT JANSEN等: "Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer", 《PTERIDINES》 *
GREGORY M CRESSWELL等: "Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells that Can Be Reprogrammed with Folate-Targeted Drugs", 《CANCER RES》 *
朱广迎主编: "《放射肿瘤学 3版》", 31 August 2015, 科学技术文献出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Also Published As

Publication number Publication date
EP3463367A1 (en) 2019-04-10
AU2017271550B2 (en) 2023-11-02
KR102489277B1 (ko) 2023-01-16
BR112018074119A2 (pt) 2019-03-06
IL263059B1 (en) 2024-10-01
RU2018145750A (ru) 2020-06-25
JP7278777B2 (ja) 2023-05-22
KR20190021261A (ko) 2019-03-05
WO2017205661A1 (en) 2017-11-30
AU2017271550A1 (en) 2018-12-06
NZ748427A (en) 2025-05-30
EP3463367A4 (en) 2020-01-29
IL263059A (en) 2018-12-31
IL263059B2 (en) 2025-02-01
US20210170035A1 (en) 2021-06-10
RU2018145750A3 (cg-RX-API-DMAC7.html) 2020-07-30
US20190216935A1 (en) 2019-07-18
CN114903890A (zh) 2022-08-16
CA3025309A1 (en) 2017-11-30
JP2019519524A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
ES2946507T3 (es) Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
CN106074368B (zh) Pfkfb3抑制剂和用作抗癌治疗剂的方法
CA3134765A1 (en) Bi-functional molecules to degrade circulating proteins
BR112021002250A2 (pt) compostos de ligação ao receptor de il-2
CN107148416B (zh) 作为新抗癌药的被取代的2,4二氨基-喹啉
CN105899491A (zh) 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
CN113956238A (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
JP2025063195A (ja) トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
EP4295917A2 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2024531258A (ja) 微小管阻害剤に基づく抗体薬物複合体
JP7278777B2 (ja) 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法
CN110312517A (zh) 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
TW201801751A (zh) 靶向構建體及其製劑
TW202222311A (zh) 結合熱休克蛋白90(hsp90)之共軛體和彼之調製劑
TW202340226A (zh) 碳酸酐酶ix配位體
JP2020515582A (ja) 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート
JP2018518509A (ja) 白金化合物、組成物及びその使用
EP4436578A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023222019A1 (zh) 配体药物偶联物及其应用
JP2021534114A (ja) 併用療法
CN115884980A (zh) 肽铂络合物及其使用方法
KR20160133005A (ko) 암 치료법의 조합
CN110678204A (zh) 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
US20230372476A1 (en) Novel use of mycobacterium tuberculosis extract

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315

RJ01 Rejection of invention patent application after publication